VERASTEM ONCOLOGY
Verastem Oncology is a biopharmaceutical company committed to the development and commercialization of medicines to improve the lives of patients diagnosed with cancer. Its portfolio consists of small molecule kinase inhibitors that inhibit critical signaling pathways, which promote cancer cell survival and tumor growth.
VERASTEM ONCOLOGY
Industry:
Biopharma Biotechnology Pharmaceutical
Founded:
2010-01-01
Address:
Needham, Massachusetts, United States
Country:
United States
Website Url:
http://www.verastem.com
Total Employee:
101+
Status:
Active
Contact:
1-781-292-4200
Email Addresses:
[email protected]
Total Funding:
379.1 M USD
Technology used in webpage:
Amazon Mobile Non Scaleable Content HSTS IPv6 CrUX Top 50m Amazon Virginia Region Microsoft CloudFront Ruby On Rails Token New Relic
Similar Organizations
Cytokinetics
Cytokinetics is a biopharmaceutical company developing therapies for debilitating diseases.
KSQ Therapeutics
KSQ Therapeutics is using CRISPR technology within a powerful drug discovery engine to enable high-confidence drug development.
NephroDI Therapeutics
NephroDI Therapeutics is a biopharmaceutical company that focuses on the concentration disorders of the kidney.
Reata Pharmaceuticals
Reata Pharmaceuticals is a biopharmaceutical company that develops drugs for cancer, inflammation, and neurodegenerative diseases.
Sirnaomics
Sirnaomics is a biopharmaceutical company developing therapeutics for critical human diseases by using RNA interference technology.
Current Advisors List
Current Employees Featured
Founder
Stock Details
Investors List
Biotechnology Value Fund
Biotechnology Value Fund investment in Post-IPO Equity - Verastem Oncology
Oxford Finance LLC
Oxford Finance LLC investment in Post-IPO Debt - Verastem Oncology
Hercules Capital
Hercules Capital investment in Post-IPO Debt - Verastem Oncology
Bessemer Venture Partners
Bessemer Venture Partners investment in Series C - Verastem Oncology
MPM Capital
MPM Capital investment in Series C - Verastem Oncology
Longwood Fund
Longwood Fund investment in Series C - Verastem Oncology
Cardinal Partners
Cardinal Partners investment in Series C - Verastem Oncology
Astellas Venture Management
Astellas Venture Management investment in Series B - Verastem Oncology
Bessemer Venture Partners
Bessemer Venture Partners investment in Series B - Verastem Oncology
MPM Capital
MPM Capital investment in Series B - Verastem Oncology
Key Employee Changes
| Date | New article |
|---|---|
| 2023-10-26 | Verastem Oncology appoints Dan Calkins as CFO |
| 2023-07-11 | Verastem Oncology promotes Dan Paterson to CEO role |
| 2021-09-22 | Verastem Oncology Appoints Louis J. Denis, M.D., as Chief Medical Officer |
Official Site Inspections
http://www.verastem.com Semrush global rank: 4.37 M Semrush visits lastest month: 2.25 K
- Host name: 136.184.190.35.bc.googleusercontent.com
- IP address: 35.190.184.136
- Location: United States
- Latitude: 38.6583
- Longitude: -77.2481
- Timezone: America/New_York
More informations about "Verastem Oncology"
Verastem Oncology | Biopharmaceutical Company
Verastem Oncology (NASDAQ: VSTM) is a biopharmaceutical company focused on exploring the unexplored to give patients diagnosed with cancer better options.See details»
Our Leadership - Verastem Oncology
Learn more about leadership team at Verastem Oncology, a group of passionate leaders from the biopharmaceutical industry.See details»
Verastem Oncology - Wikipedia
Verastem, Inc., doing business as Verastem Oncology, is an American pharmaceutical company that develops medicines to treat certain cancers. Headquartered and founded in Boston, Massachusetts, the firm is a member of NASDAQ Biotechnology Index. See details»
Verastem - Org Chart, Teams, Culture & Jobs - The Org
View Verastem's up-to-date org chart, open roles, and culture details. Find executives, board members, teams, related companies, and more.See details»
Verastem Oncology Reports First Quarter 2024 Financial Results …
Mar 31, 2024 · Verastem Oncology (Nasdaq: VSTM) is a late-stage development biopharmaceutical company committed to the development and commercialization of new …See details»
Verastem Oncology - LinkedIn
Verastem Oncology (Nasdaq: VSTM) (Verastem, Inc.) is a late-stage development biopharmaceutical company committed to the development and commercialization of new medicines to improve the lives of...See details»
Verastem Oncology - Crunchbase Company Profile
Verastem is a biopharmaceutical company that focuses on discovering and developing novel drugs that selectively target cancer stem cells. View contacts for Verastem Oncology to access new leads and connect with decision-makers.See details»
First-Of-Its-Kind, Multi-National Patient Impact
Nov 7, 2023 · Verastem Oncology (Nasdaq: VSTM) is a development-stage biopharmaceutical company committed to the development and commercialization of new medicines to improve the lives of patients diagnosed …See details»
Verastem Oncology Receives FDA Orphan Drug …
BOSTON, July 29, 2024 -- (BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients, today announced that the U.S. Food and...See details»
Verastem Oncology to Present at the 7th Annual Evercore ISI …
BOSTON, November 26, 2024--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced …See details»
Verastem Oncology Announces the Initiation of a …
BOSTON, May 24, 2024 -- (BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced that it has...See details»
Verastem Oncology Receives Breakthrough Therapy Designation …
May 24, 2021 · Verastem Oncology (Nasdaq: VSTM) is a development-stage biopharmaceutical company committed to the development and commercialization of new medicines to improve …See details»
About Verastem | Verastem Oncology
Learn about the Verastem Oncology team, culture and values. Verastem Oncology (VSTM) is a biopharmaceutical company committed to development of cancer medicines.See details»
Corporate Presentation - Verastem Oncology
This presentation includes forward -looking statements about, among other things, Verastem Oncology’s programs and product candid ates, including anticipated regulatory submissions, …See details»
Verastem Oncology Completes Rolling NDA Submission to the …
Oct 31, 2024 · BOSTON -- (BUSINESS WIRE)--Oct. 31, 2024-- Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients …See details»
Pipeline - Verastem Oncology
Preclinical models demonstrate strong tumor regression as a single agent and support approaches in combination with Verastem Oncology’s RAF/MEK clamp avutometinib as well …See details»
Verastem: Preparing For Upcoming Catalysts (NASDAQ:VSTM)
1 day ago · Verastem Oncology LGSOC Market Opportunity (Verastem Oncology) Some research analysts believe that the ovarian cancer therapeutics market is expected to hit $5.65B in 2030. …See details»
Media and Press | VSTM News | Verastem Oncology
Oct 31, 2024 · View latest Verastem Oncology VSTM news and press releases, submit your media inquiries, download press kit and corporate brochure.See details»
Nivolumab in Patients With Advanced or Metastatic Malignancies ...
1 day ago · PURPOSETo report on CheckMate 627 (ClinicalTrials.gov identifier: NCT02832167), a phase II adaptive basket design trial of nivolumab in uncommon advanced/metastatic …See details»
Verastem Oncology to Present at the 7th Annual Evercore ISI …
2 days ago · BOSTON--(BUSINESS WIRE)--Nov. 26, 2024-- Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients …See details»